• Evaluation of TMS Visual Outcome

  NCT06600932

  Not yet recruitingInterventionalNot ApplicableUpdated Sep 19, 2024
• Evaluation on Visual Outcome of TMS

  NCT06612190

  Not yet recruitingInterventionalNot ApplicableUpdated Sep 25, 2024
• Visual Functional Connectivity and Visual Improvement After TMS/Binocular Treatment

  NCT03151200

  WithdrawnInterventionalNot ApplicableUpdated May 10, 2023
• Effect of Transcranial Magnetic Stimulation on Visual Functions of Adult Amblyopia: a Preliminary Study

  NCT05393739

  Active, not recruitingInterventionalNot ApplicableUpdated Jul 20, 2026
• Repetitive Transcranial Magnetic Stimulation for Post-Stroke Visual Field Defects

  NCT04021160

  CompletedInterventionalNot ApplicableUpdated Jul 21, 2021
• TMS Enhancement of Visual Plasticity in Schizophrenia

  NCT03220438

  TerminatedInterventionalNot ApplicableUpdated Apr 18, 2025

ClinicalTrials.gov ID

NCT07425717

Lead Sponsor

Shanghai High Myopia Study GroupOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

136Estimated

Last Update Posted

Feb 23, 2026Actual

Start Date

Jun 1, 2026Estimated

Primary Completion Date

May 31, 2028Estimated

Completion Date

May 31, 2029Estimated

Official Title

Effectiveness of TMS for Visual Restoration: a Multicenter Randomized Controlled Trial

Brief Summary

The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) works to restore vision in adults with severe retinal degeneration. It will also learn about the safety of TMS treatment. The main questions it aims to answer are:

1. Does TMS treatment improve the visual function of participants?
2. What medical problems do participants have when receiving TMS treatment? Researchers will compare TMS treatment to a sham stimulation (identical procedures using a sham coil without effective magnetic field output) to see if TMS treatment works to restore their vision.

Participants will:

UndergoTMS treatment to a sham stimulation for consecutive 5 days Visit the clinic at 5 days, 4 weeks, 3 months, 6 months, 12 months after start of the treatment for checkups and tests

• Retinal Degeneration
• Vision Impairment and Blindness

• Transcranial magnetic stimulation targeting occipital visual cortex
• Sham stimulation

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• between 45 and 70 years old
• bilateral severe MMD (META-PM grades ≥ 3)
• no prior TMS history or contraindications to TMS

Exclusion Criteria:

• other significant ocular diseases, such as refractive media opacity, glaucoma, uveitis, ocular trauma, untreated retinal detachment, or lens dislocation
• received anti-vascular endothelial growth factor treatment or other ocular surgeries within 3 months
• history of epilepsy or family history of epilepsy, intracranial metal implants, or severe cerebrovascular diseases
• mental illness, cognitive impairment (MMSE score < 24), unable to communicate effectively
• severe heart disease, liver or kidney dysfunction, or coagulation disorders
• pregnant or lactating women
• currently participating in other clinical trials.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Shanghai High Myopia Study GroupOTHER

alicewen@139.com+0086-13636624399

boma1983@hotmail.com+0086-13701749192